WHY DO PRESCRIPTION DRUG PRICES INCREASE? STATE MEDICAID EXPANSION, EXECUTIVE COMPENSATION AND CORPORATE GOVERNANCE
DOI:
https://doi.org/10.47941/ijf.984Keywords:
Product Markets, Product Prices, Executive Compensation, Corporate GovernanceAbstract
We exploit a quasi-random shock, i.e., Medicaid expansion, to the demand on prescription drugs and examine its impact on drug prices conditional on manufacturing firms’ financial characteristics. We use this shock to study the role of executive compensation, board independence and corporate governance, in setting drug prices. We find suggestive evidence that drug prices increased in expansion states. We also find that stock option awards are associated with lower drug prices. This provides evidence for Ross (2004)’s magnification effect that stock options may reduce the risk-taking of a CEO. Corporate governance appears to have a more complicated relationship with drug prices. This study addresses an underrepresented area in finance and provides a blueprint for researchers in finance to utilize a unique data set to answer research questions in finance and economics.
Downloads
References
Baily. Martin Neil. (1972). Research and Development Costs and Returns: The U.S. Pharmaceutical Industry. Journal of Political Economy.
Bakke. Mahmudi. Fernando, and Salas. (2016). The Causal Effect of Option Pay on Corporate Risk Management. Journal of Financial Economics.
Bargeron, Lehn, and Zutter. (2010). Sarbanes-Oxley and Corporate Risk-taking. Journal of Accounting and Economics.
Berman, Aaron, Theodore Lee. Adam Pan, Zain Rizvi, and Arielle Thomas. (2017). Curbing Unfair Drug Prices: A Primer for States. Yale Law School.
Berndt, Ernst R. (2019). Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price. Journal of Economic Perspectives.
Bonaime, Alice A. and Wang, Ye. (2019) Mergers, Product Prices, and Innovation: Evidence from the Pharmaceutical Industry. SSRN.
Chen, Steiner, and Whyte. (2006). Does Stock Option-based Executive Compensation Induce Risk-taking? An Analysis of the Banking Industry. Journal of Banking and Finance.
Dimasi, Grabowski, and Hansen. (2016). Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. Journal of Health Economics.
Ghosh, A., Simon, K., & Sommers, B. D. (2017). The effect of state Medicaid expansions on prescription drug use: evidence from the Affordable Care Act (No. w23044). National Bureau of Economic Research.
Gompers, Paul, Ishi, Joy, and Metrick, Andrew. (2003). Corporate Governance and Equity Prices. The Quarterly Journal of Economics.
Grabowski, Henry. (2002). Patents, Innovation and Access to New Pharmaceuticals. Journal of International Economic Law.
Grabowski, Henry G. Margaret Kyle, Richard Mortimer, Genia Long, and Noam Kirson. (2011). Evolving Brand-name and Generic Drug Competition May Warrant a Revision of the Hatch-Waxman Act. Health Affairs.
Grabowski, Henry, and John Vernon. (1992). Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics.
Hammoudeh, Mosab and Nain, Amrita. (2019). Seeking Efficiency or Price Gouging? Evidence from Pharmaceutical Mergers. SSRN.
Garfinkel, Jon A. and Hammoudeh, Mosab. (2020). Competition and Innovation Revisited: A Product-Level View. SSRN.
Jacobs, Lawrence R., and Timothy Callaghan. (2013). Why states expand Medicaid: Party, resources, and history. Journal of Health Politics, Policy and Law.
Manso, Gustavo. (2011). Motivating innovation. Journal of Finance.
Mehran, Hamid. (1995). Executive Compensation Structure, Ownership, and Firm Performance. Journal of Financial Economics.
Pathan. Shams. (2009). Strong Boards, CEO Power and Bank Risk-taking. Journal of Banking and Finance.
Ross, Stephen A. (2004). Compensation, Incentives, and the Duality of Risk Aversion and Riskiness. Journal of Finance.
Shue, Kelly. and Townsend, Richard. (2017). How Do Quasi-Random Option Grants Affect CEO Risk-Taking? The Journal of Finance.
Mitchell A. Petersen. (2009). Estimating Standard Errors in Finance Panel Data Sets: Comparing Approaches. The Review of Financial Studies.
Young, Katherine, and Rachel Garfield. (2018). Snapshots of Recent State Initiatives in Medicaid Prescription Drug Cost Control. The Henry J. Kaiser Family Foundation
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Mosab Hammoudeh, Amrita Nain, Tarek Zaher
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
